Exelixis: STELLAR-303 最終OS解析（肝転移なし）2026年半ば

The document states the STELLAR-303 final analysis of the second dual primary endpoint (OS in patients without liver metastases) is expected mid-2026. This is the next regulatory readout for the NDA already under FDA review for zanzalintinib + atezolizumab in previously treated CRC.

主要事実

提出: 2026年1月12日 21:22
イベント: PDUFA 日設定
方向: 中立
企業: EXELエクセリクシス
アセット: zanzalintinib
出典: SEC 8-K
信頼度: 出典あり

出典の抜粋

EX-99.1 2 exel20260111exhibit991.htm EX-99.1 Document Exhibit 99.1 Investor Contacts: Andrew Peters SVP, Strategy and Investor Relations Exelixis, Inc. 650-837-7248 apeters@exelixis.com Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Media Contact: Hal Mackins For Exelixis, Inc. 415-994-0040 hal@torchcommunications.com Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 – Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion – – Presentation and webcast at J.P. Morgan 2026 Healthcare Conference to

SEC 8-K